In the years before biosimilar entry, AbbVie invested aggressively in building out its immunology pipeline acquiring Allergan for $63 billion in 2020, a transaction that added Botox, Juvederm, and a range of non-Humira products to the portfolio [30]
Materials and methods: To explore the potential genetic factors involved in the risk of T2D, we gathered the genotype information of two large T2D genetic datasets (~500,000 participants from the UK Biobank, ~70,000 individuals from the 70KforT2D)
Yet one leading risk factor obesity has been largely untouched by this innovation wave
Their ability to modulate biological repair mechanisms at a cellular level aligns perfectly with the goals of modern orthobiologic care: faster healing, fewer side effects, and better long-term outcomes
Theyre looking for sustainable health improvements that last well beyond any medication protocol